337902-75-7

Upstream product

• 337902-71-3 4-thiocarbamoylpiperidine-1-carboxylic acid ethyl ester 
• 302839-10-7 2-bromo-1-(4-fluorophenyl)-2-(2-fluoropyridin-4-yl)ethanone 

Downstream Products

• 337902-35-9 4-(4-Fluorophenyl)-2-(piperidin-4-yl).5-(2-(1-(S)-phenylethyl)amino-4-pyridinyl)thiazole 
• 337902-76-8 4-{4-(4-Fluoro-phenyl)-5-[2-((S)-1-phenyl-ethylamino)-pyridin-4-yl]-thiazol-2-yl}-piperidine-1-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

A library of trisubstituted oxazoles, thiazoles, imidazoles (1,2,4- and 2,4,5-substituted) and imidazo[1,2-b]pyridines was prepared and evaluated in vitro as p38α inhibitors and in vivo in several models of rheumatoid arthritis. Four structures - 32, 37,

Thiazole compounds and their pharmaceutical use

Compounds of formula (I) and pharmaceutically-acceptable and -cleavable esters thereof and acid addition salts thereof, wherein the symbols are as defined are MAP kinase inhibitors, useful pharmaceutically for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.